Public Relations
Public Relations
Cubist Pharmaceuticals Announces Successful Human Proof-of-Principal Study Using Oral Formulations of Ceftriaxone
LEXINGTON, Mass., Jan 7, 2002 -- Cubist Pharmaceuticals, Inc. today announced successful results from a human clinical research study examining the bioavailability of ceftriaxone in a variety of oral formulations.In these studies, intended to determine whether certain formulations could make ceftriaxone bioavailable, Cubist achieved its goal, demonstrating clinically relevant blood levels of ceftriaxone delivered intraduodenally.....
Click here to View Full Publication
Press Release
Dated: Jan 7, 2002
Cubist Pharmaceuticals Announces Issuance of Patent Covering Oral Formulations of Ceftrixone
Cubist Expects to Conduct Proof-of-Principle Studies in Man by End of 2001 CAMBRIDGE, Mass., June 19 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced the issuance by the United States Patent and Trademark Office of patent number 6,248,360, entitled "Complexes to Improve Oral Absorption of Poorly Absorbable Antibiotics." The patent, assigned to International Health Management Associates, Inc. (IHMA), covers.....
Click here to View Full Publication
Press Release
Dated: June 19, 2001
Cubist Pharmaceuticals Acquires Rights to Oral Ceftriaxone from IHMA
First Orally Active Formulation of the World's Largest-Selling IV antibiotic, Rocephin(R)
CAMBRIDGE, Mass., Nov. 27 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that it has acquired worldwide rights to oral ceftriaxone from International Health Management Associates, Inc. (IHMA), a privately held company outside Chicago. This formulation is the first ....
Click here to View Full Publication
Press Release
Dated: November 27, 2000